Announcements Trials
Browse Landscape

Phase

Phase 3 16Phase 1 8Phase 1/2 5Phase 2 3Phase 4 2Phase NA 1Phase 2/3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Lymphoid 1

Conditions

Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1ALK or ROS1-positive NSCLC 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Crizotinib × Clear all
NCT05160922 2026-03-30

Crizotinib Continuation Clinical Study

Pfizer

Phase 4 Active not recruiting
27 enrolled
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Pfizer

Phase 4 Terminated
41 enrolled 9 charts
Thoracic

ALK or ROS1-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡